HTA Database - Search Results

Sort by Relevance

Search Results [341 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Swiss Federal Office of Public Health (FOPH)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS)
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Selumetinib (reassessment after the deadline: neurofibromatosis (≥ 3 to < 18 years, type 1))]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of acute lower GI bleeding
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: osseointegration of bone-anchored prostheses in individuals living with lower limb amputation(s)]
2023	NIHR Health Technology Assessment programme	Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
2023	NIHR Health Technology Assessment programme	Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023	NIHR Health Technology Assessment programme	Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2023	NIHR Health and Social Care Delivery Program	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	NIHR Health Technology Assessment programme	Posterior cervical foraminotomy versus anterior cervical discectomy for cervical brachialgia: the FORVAD RCT
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	NIHR Health Services and Delivery Research programme	The effectiveness of sexual assault referral centres with regard to mental health and substance use: a national mixed-methods study – the MiMoS Study
2023	Canary Health Service	[Software applications for prevention and intervention in people at risk of suicide: effectiveness, safety and cost-effectiveness]
2023	Canary Health Service	[Effectiveness and safety of bioelectrical stimulation techniques in fibromyalgia: systematic review]
2023	Canary Health Service	[Evaluation of the lung cancer screening program]
2023	NIHR Health Technology Assessment programme	Pragmatic randomised controlled trial of guided self-help versus individual cognitive behavioural therapy with a trauma focus for post-traumatic stress disorder (RAPID)
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023	Health Sciences Institute in Aragon (IACS)	[Effectiveness, safety and efficiency of subconjunctival drainage devices using an ab-internal approach for primary open-angle glaucoma surgery]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Valoctocogene roxaparvovec (severe haemophilia A)]
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: continuum of care and services for individuals with a traumatic spinal cord injury in Québec - characteristics, care pathways and clinical outcomes for adults from 2014 to 2020]
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	(Cost-effectiveness evaluation of Valbenazine (Dysval) for tardive dyskinesia)
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of gefapixant (Lyfnua)]
2023	Norwegian Institute of Public Health (NIPH)	[Surgery for degenerative rotator cuff tears: a health technology assessment]
2023	NIHR Health Technology Assessment programme	Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pembrolizumab for head and neck cancer]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous transvascular implantation of a coronary sinus reducing stent. Update 2022
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2022	Malaysian Health Technology Assessment (MaHTAS)	Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Bronchial thermoplasty in severe asthma]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022	Health Technology Wales (HTW)	Virtual reality interventions for the management of pain associated with medical procedures
2022	Norwegian Institute of Public Health (NIPH)	[Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Selumetinib (neurofibromatosis (≥ 3 to < 18 years, type 1))]
2022	Norwegian Institute of Public Health (NIPH)	Zephyr® valves system in the treatment of emphysema: a single technology assessment
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vagus nerve stimulation for drug-resistant epilepsy]
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Sentinel lymph node biopsy in oral cavity carcinoma: clinical effectiveness, safety, and cost-effectiveness]
2021	Health Technology Wales (HTW)	Transcranial magnetic stimulation for the treatment of depression
2021	Swiss Federal Office of Public Health (FOPH)	Statins in the primary prevention of cardiovascular events and mortality in Switzerland
2021	NIHR Health Technology Assessment programme	Prognostic models of survival in patients with advanced incurable cancer: the PiPS2 observational study
2021	NIHR Health Technology Assessment programme	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation
2021	Malaysian Health Technology Assessment (MaHTAS)	Delirium unit in geriatric ward
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: efficacy and safety of pharmacological treatments for alcohol withdrawal and relapse prevention]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Osilodrostat (Endogenous Cushing’s Syndrome)]
2021	Canary Health Service	[Molecular markers for the detection of clinically significant prostate cancer]
2021	Ontario Health	Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment
2021	Swiss Federal Office of Public Health (FOPH)	Medical cannabis for treating various symptoms in Switzerland
2021	Swiss Federal Office of Public Health (FOPH)	Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	Ontario Health	Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2020	NIHR Health Services and Delivery Research programme	UK Study of tendon Achilles Rehabilitation multicentre randomised clinical trial (UK STAR)
2020	Malaysian Health Technology Assessment (MaHTAS)	Programmatic management of latent tuberculosis infection
2020	Swiss Federal Office of Public Health (FOPH)	Iron therapy for iron deficiency without anemia
2020	NIHR Health Technology Assessment programme	Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2020	National Committee for Technology Incorporation (CONITEC)	[Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: prevention of cardiovascular events and safety of SGLT2 inhibitors compared to DPP-4 inhibitors in a real-world setting in patients with type 2 diabetes]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	Andalusian Health Technology Assessment Area (AETSA)	Genetic risk prediction test for cardiovascular disease
2020	NIHR Health Technology Assessment programme	Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy and safety of mechanical thrombectomy in the treatment of patients with ischaemic stroke beyond 6 hours after onset or with an unknown time of onset]
2019	NIHR Health Technology Assessment programme	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation
2019	Norwegian Institute of Public Health (NIPH)	Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab. A health technology assessment
2019	Norwegian Institute of Public Health (NIPH)	Prehospital CT for early diagnosis and treatment of suspected acute stroke or severe head injury
2019	Norwegian Institute of Public Health (NIPH)	Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission
2019	Swiss Federal Office of Public Health (FOPH)	Removal of osteosynthesis materials (e.g. screws, plates, nails and wires) used to treat bone fractures
2019	The Regional Health Technology Assessment Centre (HTA-centrum)	Impact of postmastectomy radiotherapy on complications and results of immediate breast reconstruction
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Shear-wave elastography for liver fibrosis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Teriparatide in biphosphonate-resistant osteoporosis and high fracture risk]
2019	Ontario Health	Osseointegrated Prosthetic Implants for People With Lower-Limb Amputation: A Health Technology Assessment
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: respiratory multiplex NAAT (8 or more targets)]
2018	NIHR Health Technology Assessment programme	Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT
2018	NIHR Health Technology Assessment programme	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews
2018	Adelaide Health Technology Assessment (AHTA)	Anti-Mullerian Hormone (AMH) testing for female patients who will or have received gonadotoxic treatment
2018	Andalusian Health Technology Assessment Area (AETSA)	Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. EUnetHTA adopted HTA report.
2018	Basque Office for Health Technology Assessment (OSTEBA)	[HIFU —High intensity focused ultrasound— in essential tremor]
2018	NIHR Health Technology Assessment programme	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2017	HAYES, Inc.	Impella 2.5 System (Abiomed Inc.) for cardiac support in patients undergoing high-risk percutaneous coronary intervention
2017	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: update of proton radiation therapy indications in oncology]
2017	Norwegian Institute of Public Health (NIPH)	Sutureless aortic valve replacement for treatment of severe aortic stenosis: A single technology assessment of Perceval sutureless aortic valve
2017	Belgian Health Care Knowledge Centre (KCE)	Anticoagulants in non-valvular atrial fibrillation
2017	HAYES, Inc.	Coronary artery calcium scoring for risk assessment and stratification of coronary artery disease in asymptomatic adults
2017	NIHR Health Services and Delivery Research programme	SUPPORT-HF 2 (Seamless User-centred Proactive Provision Of Risk-stratified Treatment for Heart Failure) - An internal pilot phase of a planned large-scale randomised trial of an integrated, technology-enabled care delivery model
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Trabecular bone score-TBS for bone fragility diagnosis]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Evaluation of the utility and indication of prostate biopsies with image fusion – magnetic resonance and transrectal ultrasound]
2016	Health Quality Ontario (HQO)	Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: OHTAC recommendation
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of biventricular pacing in atrioventricular heart block
2016	Canary Health Service	[Prognostic genomic tests for localized prostate cancer]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Prevention of Type 2 Diabetes Mellitus in Primary Health Care through healthy lifestyles: care and recommended clinical interventions]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Interventions to improve CPAP treatment adherence in patients with obstructive sleep apnea]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[The status and dissemination plan of clinical practice guidelines in Korea]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2015	Haute Autorite de sante (HAS)	[Measurement of nitric oxide (NO) in exhaled air]
2015	NIHR Health Services and Delivery Research programme	The Birthplace in England national prospective cohort study: further analyses to enhance policy and service delivery decision-making for planned place of birth
2015	Agency for Healthcare Research and Quality (AHRQ)	Diagnosis of right lower quadrant pain and suspected acute appendicitis
2015	Health Quality Ontario (HQO)	Is Transient Ischemic Attack a Medical Emergency? OHTAC Recommendation
2015	NIHR Health Technology Assessment programme	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling